DE19947456A1
(de)
|
1999-10-02 |
2001-04-05 |
Aventis Pharma Gmbh |
C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
US8623379B2
(en)
|
2000-03-02 |
2014-01-07 |
Emory University |
Compositions and methods for generating an immune response
|
DE60234018D1
(de)
|
2001-03-08 |
2009-11-26 |
Univ Emory |
Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene
|
DE10114178A1
(de)
*
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
PL366851A1
(en)
*
|
2001-08-22 |
2005-02-07 |
Aventis Pharma Deutschland Gmbh |
Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
|
CN1635900A
(zh)
*
|
2001-08-28 |
2005-07-06 |
伊莱利利公司 |
Glp-1和基础胰岛素的预混合物
|
US7399777B2
(en)
*
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
PT1425014E
(pt)
|
2001-08-31 |
2007-03-30 |
Sanofi Aventis Deutschland |
Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
|
CA2463803A1
(fr)
*
|
2001-10-19 |
2003-05-01 |
Eli Lilly And Company |
Melanges biphasiques de glp-1 et d'insuline
|
US20050250676A1
(en)
*
|
2001-11-19 |
2005-11-10 |
Aventis Pharma Deutschland Gmbh |
Method of activating insulin receptor substrate-2 to stimulate insulin production
|
WO2003053460A1
(fr)
*
|
2001-12-19 |
2003-07-03 |
Eli Lilly And Company |
Compositions cristallines pour reguler la glycemie
|
US7078404B2
(en)
*
|
2002-04-11 |
2006-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7223796B2
(en)
*
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
AU2003236201A1
(en)
*
|
2002-05-07 |
2003-11-11 |
Novo Nordisk A/S |
Soluble formulations comprising monomeric insulin and acylated insulin
|
US7049341B2
(en)
*
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
US7262220B2
(en)
*
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
DE10231370B4
(de)
*
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
MXPA05000053A
(es)
*
|
2002-07-12 |
2005-04-08 |
Aventis Pharma Gmbh |
Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos.
|
US20040157922A1
(en)
*
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
*
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
US7193035B2
(en)
*
|
2002-10-29 |
2007-03-20 |
Sanofi-Aventis Deutschland Gmbh |
Crystals of insulin analogs and processes for their preparation
|
DE10250297A1
(de)
*
|
2002-10-29 |
2004-05-19 |
Aventis Pharma Deutschland Gmbh |
Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
|
US20040138099A1
(en)
*
|
2002-11-29 |
2004-07-15 |
Draeger Eberhard Kurt |
Insulin administration regimens for the treatment of subjects with diabetes
|
DE10258008B4
(de)
*
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US20040242583A1
(en)
*
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
*
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
DE10306250A1
(de)
|
2003-02-14 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7196114B2
(en)
*
|
2003-02-17 |
2007-03-27 |
Sanofi-Aventis Deutschland Gmbh |
Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
|
DE10308355A1
(de)
*
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308352A1
(de)
*
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308351A1
(de)
*
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7173151B2
(en)
*
|
2003-02-27 |
2007-02-06 |
Sanofi-Aventisdeutschand Gmbh |
Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
|
US7148246B2
(en)
*
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US7501440B2
(en)
*
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
DE10314610A1
(de)
*
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
US20050054818A1
(en)
*
|
2003-07-02 |
2005-03-10 |
Brader Mark Laurence |
Crystalline compositions for controlling blood glucose
|
US7094800B2
(en)
*
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7008957B2
(en)
*
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
SI1648933T1
(sl)
*
|
2003-07-25 |
2010-01-29 |
Conjuchem Biotechnologies Inc |
Dolgo delujoäś inzulinski derivat in metoda zanj
|
US7094794B2
(en)
*
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
*
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
DK2275439T3
(da)
|
2003-08-05 |
2014-05-12 |
Novo Nordisk As |
Hidtil ukendte insulinderivater
|
US7241787B2
(en)
*
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
US7470706B2
(en)
*
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7498341B2
(en)
*
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7402674B2
(en)
*
|
2004-01-31 |
2008-07-22 |
Sanofi-Aventis Deutschland Gmbh, |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(de)
*
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
GT200500063A
(es)
|
2004-04-01 |
2005-10-14 |
|
Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
|
DE602004004631D1
(de)
|
2004-04-01 |
2007-03-22 |
Sanofi Aventis Deutschland |
Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
US8343914B2
(en)
*
|
2006-01-06 |
2013-01-01 |
Case Western Reserve University |
Fibrillation resistant proteins
|
JP2009527526A
(ja)
*
|
2006-02-21 |
2009-07-30 |
ノボ・ノルデイスク・エー/エス |
単鎖インスリンのアナログとその製薬的製剤
|
CN101443314B
(zh)
*
|
2006-03-13 |
2014-04-09 |
杏林制药株式会社 |
作为gsk-3抑制剂的氨基喹诺酮类
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
EP2061767B1
(fr)
|
2006-08-08 |
2014-12-17 |
Sanofi |
Imidazolidin-2,4-diones arylaminoaryl-alkyl-substituées, procédé de fabrication, médicaments les contenant et leur utilisation
|
ES2554773T3
(es)
*
|
2006-10-04 |
2015-12-23 |
Case Western Reserve University |
Insulina y análogos de la insulina resistentes a la fibrilación
|
DE102007002260A1
(de)
*
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
EP2025674A1
(fr)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
|
JP5426552B2
(ja)
*
|
2007-09-11 |
2014-02-26 |
杏林製薬株式会社 |
Gsk−3阻害剤としてのシアノアミノキノロン及びテトラゾロアミノキノロン
|
MX2010002662A
(es)
|
2007-09-12 |
2010-04-09 |
Activx Biosciences Inc |
Aminoquinolonas espirociclicas como inhibidores de gsk-3.
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
DE102007063671A1
(de)
*
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
JP5547083B2
(ja)
|
2007-11-20 |
2014-07-09 |
アンブルックス,インコーポレイテッド |
修飾されたインスリンポリペプチドおよびそれらの使用
|
AU2009203810B2
(en)
|
2008-01-09 |
2013-07-25 |
Sanofi-Aventis Deutschland Gmbh |
Novel insulin derivatives having an extremely delayed time-action profile
|
AU2009203809B2
(en)
|
2008-01-09 |
2013-07-25 |
Sanofi-Aventis Deutschland Gmbh |
Novel insulin derivatives having an extremely delayed time-action profile
|
WO2009097995A1
(fr)
*
|
2008-02-07 |
2009-08-13 |
Sanofi-Aventis |
Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
US8993516B2
(en)
*
|
2008-04-14 |
2015-03-31 |
Case Western Reserve University |
Meal-time insulin analogues of enhanced stability
|
NZ588857A
(en)
*
|
2008-04-22 |
2012-07-27 |
Univ Case Western Reserve |
Isoform-specific insulin analogue for control blood sugar levels
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
WO2010003624A2
(fr)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
|
KR20120129875A
(ko)
*
|
2008-07-31 |
2012-11-28 |
케이스 웨스턴 리저브 유니버시티 |
염소화 아미노산을 갖는 인슐린 유사체
|
US9200053B2
(en)
|
2008-07-31 |
2015-12-01 |
Case Western Reserve University |
Insulin analogues containing penta-fluoro-Phenylalanine at position B24
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
EP3228320B1
(fr)
|
2008-10-17 |
2019-12-18 |
Sanofi-Aventis Deutschland GmbH |
Combinaison d'une insuline et d'un antagoniste glp 1
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
WO2010068601A1
(fr)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
|
WO2010104205A1
(fr)
*
|
2009-03-11 |
2010-09-16 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones comme inhibiteurs de la gsk-3
|
SG176985A1
(en)
*
|
2009-07-09 |
2012-01-30 |
Biocon Ltd |
A preparative non-linear gradient based chromatographic method and purified products thereof
|
JP5738291B2
(ja)
|
2009-07-31 |
2015-06-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリンリンカー複合体を含むプロドラッグ
|
AU2010277560B2
(en)
|
2009-07-31 |
2014-12-11 |
Sanofi-Aventis Deutschland Gmbh |
Long acting insulin composition
|
CN102482312A
(zh)
|
2009-08-26 |
2012-05-30 |
赛诺菲 |
新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
|
US8399407B2
(en)
*
|
2009-09-17 |
2013-03-19 |
Case Western Reserve University |
Non-standard insulin analogues
|
WO2011039338A2
(fr)
|
2009-10-02 |
2011-04-07 |
Sanofi-Aventis |
Utilisation de composés à activité inhibitrice de sglt-1/sglt-2 pour produire des médicaments pour le traitement de maladies osseuses
|
UY33025A
(es)
|
2009-11-13 |
2011-06-30 |
Sanofi Aventis Deustschland Gmbh |
Composicion farmaceutica que comprende un agonista de glp-1 metionina
|
AR080669A1
(es)
|
2009-11-13 |
2012-05-02 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
|
CN102762589A
(zh)
|
2009-12-11 |
2012-10-31 |
卡斯西部储备大学 |
带有氯化氨基酸的胰岛素类似物
|
WO2011107494A1
(fr)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
US8853155B2
(en)
|
2010-06-23 |
2014-10-07 |
Novo Nordisk A/S |
Insulin derivatives containing additional disulfide bonds
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
MX346786B
(es)
|
2010-08-17 |
2017-03-31 |
Ambrx Inc |
Polipeptidos de relaxina modificados y sus usos.
|
MX339614B
(es)
|
2010-08-30 |
2016-06-02 |
Sanofi - Aventis Deutschland GmbH |
Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
|
EP2438930A1
(fr)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Promédicaments comprenant un conjugué de liaison d'exendine
|
US20140011733A1
(en)
|
2011-01-20 |
2014-01-09 |
Zealand Pharma A/S |
Combination of acylated glucagon analogues with insulin analogues
|
WO2012120058A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
WO2012120056A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
|
EP2683703B1
(fr)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
|
WO2012120054A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
|
WO2012120055A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
|
WO2012120053A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
|
EP2683702B1
(fr)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
|
EP2683698B1
(fr)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
WO2013010048A2
(fr)
|
2011-07-13 |
2013-01-17 |
Case Western Reserve University |
Analogues d'insuline non standard
|
US10995129B2
(en)
*
|
2011-07-13 |
2021-05-04 |
Case Western Reserve University |
Non-standard insulin analogues
|
RU2650616C2
(ru)
|
2011-08-29 |
2018-04-16 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
WO2013037390A1
(fr)
|
2011-09-12 |
2013-03-21 |
Sanofi |
Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
|
EP2567959B1
(fr)
|
2011-09-12 |
2014-04-16 |
Sanofi |
Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
|
EP2760862B1
(fr)
|
2011-09-27 |
2015-10-21 |
Sanofi |
Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
|
WO2013151664A1
(fr)
*
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Polynucléotides modifiés pour la production de protéines
|
AR090843A1
(es)
|
2012-05-09 |
2014-12-10 |
Lilly Co Eli |
Tratamiento para diabetes comorbida con enfermedad renal cronica
|
US20130315891A1
(en)
|
2012-05-25 |
2013-11-28 |
Matthew Charles |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
CA2880085C
(fr)
|
2012-06-04 |
2021-09-07 |
Diamedica Inc. |
Isoformes de glycosylation de la kallikreine-1 tissulaire d'origine humaine
|
JP6829928B2
(ja)
|
2014-10-06 |
2021-02-17 |
ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University |
二相性単鎖インスリン類似体
|
CN107206058A
(zh)
|
2014-12-12 |
2017-09-26 |
赛诺菲-安万特德国有限公司 |
甘精胰岛素/利西拉来固定比率配制剂
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
WO2018165551A1
(fr)
|
2017-03-09 |
2018-09-13 |
Diamedica Inc. |
Formes posologiques de kallicréine tissulaire 1
|